1. Home
  2. CRGX vs NTCL Comparison

CRGX vs NTCL Comparison

Compare CRGX & NTCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • NTCL
  • Stock Information
  • Founded
  • CRGX 2021
  • NTCL 2003
  • Country
  • CRGX United States
  • NTCL China
  • Employees
  • CRGX N/A
  • NTCL N/A
  • Industry
  • CRGX
  • NTCL
  • Sector
  • CRGX
  • NTCL
  • Exchange
  • CRGX Nasdaq
  • NTCL NYSE
  • Market Cap
  • CRGX 190.0M
  • NTCL 193.8M
  • IPO Year
  • CRGX 2023
  • NTCL 2024
  • Fundamental
  • Price
  • CRGX $4.20
  • NTCL $1.59
  • Analyst Decision
  • CRGX Hold
  • NTCL
  • Analyst Count
  • CRGX 7
  • NTCL 0
  • Target Price
  • CRGX $4.67
  • NTCL N/A
  • AVG Volume (30 Days)
  • CRGX 591.0K
  • NTCL 974.1K
  • Earning Date
  • CRGX 08-11-2025
  • NTCL 01-01-0001
  • Dividend Yield
  • CRGX N/A
  • NTCL N/A
  • EPS Growth
  • CRGX N/A
  • NTCL N/A
  • EPS
  • CRGX N/A
  • NTCL N/A
  • Revenue
  • CRGX N/A
  • NTCL $10,101,647.00
  • Revenue This Year
  • CRGX $57.81
  • NTCL N/A
  • Revenue Next Year
  • CRGX N/A
  • NTCL N/A
  • P/E Ratio
  • CRGX N/A
  • NTCL N/A
  • Revenue Growth
  • CRGX N/A
  • NTCL N/A
  • 52 Week Low
  • CRGX $3.00
  • NTCL $1.09
  • 52 Week High
  • CRGX $25.45
  • NTCL $51.80
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 44.13
  • NTCL N/A
  • Support Level
  • CRGX $4.07
  • NTCL N/A
  • Resistance Level
  • CRGX $4.31
  • NTCL N/A
  • Average True Range (ATR)
  • CRGX 0.17
  • NTCL 0.00
  • MACD
  • CRGX -0.03
  • NTCL 0.00
  • Stochastic Oscillator
  • CRGX 18.62
  • NTCL 0.00

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

About NTCL NETCLASS TECHNOLOGY INC

Netclass Technology Inc is a business-to-business smart education specialist, providing IT solutions to schools, training institutions, corporations, public agencies and other institutions or corporate customers. It offers SaaS subscription service and application development. The solution's modules include teaching management, campus management, online teaching, online examination, epidemic prevention and control, education credit blockchain system, and lecturer evaluation services.

Share on Social Networks: